Novavax covid shot 93% effective against variants in trial
The Peninsula
Novavax Inc.’s Covid-19 vaccine candidate showed strong efficacy against the coronavirus, including mutated variants, in a large trial.
The shot was 90% effective at preventing symptomatic Covid and 100% effective at preventing moderate and severe symptoms, the U.S. biotech firm said Monday. The shot was 93% effective against variants of concern, it said. Novavax shares rose 8.5% in premarket U.S. trading.More Related News